Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. · 2009
Read Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. by Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2679223.txt.
Introduction
Mitchell and colleagues worked out in 2009 how the HIV protein Vpu clears a cell defense called BST-2, or tetherin, from the cell surface. Tetherin tethers new virus particles to the cell, stopping their release. Vpu defeats it, but the steps were unknown.
The team showed Vpu recruits a cell protein, beta-TrCP, part of a tagging machine that marks proteins for disposal. Mutations breaking the handshake in Vpu blocked both tetherin removal and virus release, and even poisoned normal Vpu. A second cell adaptor, AP-2, was also needed, though it did not speed tetherin's intake. Instead, Vpu reroutes tetherin after intake toward the cell's acid-filled disposal sacs, where some is destroyed. Blocking acid in those sacs halted the loss. With tetherin gone from the surface, virus buds no longer sat trapped beside it.
Catalog record
| CREATOR | Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking By Richard S Mitchell, Chris Katsura, Mark A Skasko, Katie Fitzpatrick, David Lau, Autumn Ruiz, Edward B Stephens, Florence Margottin-Goguet, Richard Benarous, John C Guatelli, Thomas J Hope Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1000450 ABSTRACT Abstract The interferon-induced transmembrane protein BST-2/CD317 (tetherin) restricts the release of diverse enveloped viruses from infected cells. The HIV-1 accessory protein Vpu antagonizes this restriction by an unknown mechanism that likely involves the down-regulation of BST-2 from the cell surface. Here, we show that the optimal removal of BST-2 from the plasma membrane by Vpu requires the cellular protein β-TrCP, a substrate adaptor for a multi-subunit SCF E3 ubiquitin ligase complex and a known Vpu-interacting protein. β-TrCP is also required for the optimal enhancement of virion-release by Vpu. Mutations in the DSGxxS β-TrCP binding-motif of Vpu impair both the down-regulation of BST-2 and the enhancement of virion-release. Such mutations also confer dominant-negative activity, consistent with a model in which Vpu links BST-2 to β-TrCP. Optimal down-regulation of BST-2 from the cell surface by Vpu also requires the endocytic clathrin adaptor AP-2, although the rate of endocytosis is not increased; these data suggest that Vpu induces post-endocytic membrane trafficking events whose net effect is the removal of BST-2 from the cell surface. In addition to its marked effect on cell-surface levels, Vpu modestly decreases the total cellular levels of BST-2. The decreases in cell-surface and intracellular BST-2 are inhibited by bafilomycin A1, an inhibitor of endosomal acidification; these data suggest that Vpu induces late endosomal targeting and partial degradation of BST-2 in lysosomes. The Vpu-mediated decrease in surface expression is associated with reduced co-localization of BST-2 and the virion protein Gag along the plasma membrane. Together, the data support a model in which Vpu co-opts the β-TrCP/SCF E3 ubiquitin ligase complex to induce endosomal trafficking events that remove BST-2 from its site of action as a virion-tethering factor. INTRODUCTION HIV-1 encodes specific proteins dedicated to counteracting host cell “restriction factors” that inhibit viral replication [1]. In the prototypic example of this relationship, the accessory protein Vif, found in almost all lentiviruses, targets cytidine deaminases in the APOBEC family for proteasomal degradation [2]; these cellular enzymes would otherwise damage nascent viral cDNAs to inhibit infectivity [3]. In the second example of this host-pathogen relationship, the accessory protein Vpu, found almost exclusively in HIV-1 and SIVcpz, counteracts the cellular transmembrane protein BST-2/CD317 (tetherin) [4],[5]. BST-2 is an interferon-induced, cell-surface and lipid-raft associated protein that tethers nascent, fully formed HIV-1 virions to infected cells, preventing their release and subsequent spread [4]–[8]. Vpu decreases the expression of BST-2 at the cell surface [5],[9], and the removal of BST-2 from its site of tethering action may underlie the mechanism by which Vpu counteracts this cellular restriction [5]. However, how Vpu reduces the levels of BST-2 at the cell-surface is currently unknown. Vpu is a small, transmembrane protein that, in addition to enhancing the release of virions from infected cells [10]–[13], induces the degradation of CD4, and possibly class I MHC, by linking these proteins to the multi-subunit SCF (Skp1-Cullin-F-box)/β-TrCP containing E3 ubiquitin ligase complex [14],[15]. Vpu recruits β-TrCP to membranes of the endoplasmic reticulum to trigger the proteasomal degradation of CD4 [14]. This process requires the interaction of Vpu with β-TrCP [14]. This interaction is mediated by a canonical DpSGxxpS sequence (where pS indicates phosphoserine) in the cytoplasmic domain of Vpu and a propeller-like arrangement of WD repeats in β-TrCP [16],[17]. β-TrCP interacts via its F-box domain with Skp1 and the remainder of the Cullin-1-based E3 ligase complex, leading to the presumed ubiquitination of CD4 and the targeting of CD4 to the proteasome. The conserved serines in the DpSGxxpS sequence of Vpu are required for the efficient down-regulation of cell-surface BST-2 as well as for the degradation of CD4 [5],[18]. However, Vpu-mediated down-regulation of BST-2 is not effectively blocked by inhibition of the proteasome [5], raising the possibility that Vpu recruits β-TrCP to induce ubiquitin-mediated endosomal trafficking events that remove BST-2 from the cell surface. Furthermore, although the serine residues in the DpSGxxpS sequence contribute to the enhancement of virion-release by Vpu, they are not absolutely required for this activity [5],[18],[19]. This observation has left the role of surface down-regulation in the counteraction of BST-2 by Vpu unresolved. Here, we show that β-TrCP is required for both the optimal down-regulation of BST-2 and the enhancement of HIV-1 virion-release by Vpu. Vpu-mediated down-regulation of BST-2 from the cell surface is also partly dependent on the plasma membrane associated clathrin adaptor protein complex AP-2 and can be inhibited by disruption of the endo-lysosomal pH gradient. These data suggest that Vpu recruits β-TrCP to induce ubiquitin-mediated endosomal trafficking events that reduce the levels of BST-2 on the plasma membrane, effectively removing BST-2 from its site of action as a virion-tethering factor. RESULTS β-TrCP is required for optimal down-regulation of BST-2 and enhancement of virion-release by Vpu To test the hypothesis that β-TrCP plays a role in the Vpu-mediated down-regulation of BST-2 from the cell surface, we over-expressed a β-TrCP mutant with a deletion in the F-box domain (ΔF-box β-TrCP). β-TrCP binds Vpu via its WD domain, while it binds to the SCF E3 ubiquitin ligase complex via its F box domain. Since ΔF-box β-TrCP binds Vpu but cannot link it and any Vpu-interacting proteins to the ubiquitination machinery, it functions as a dominant negative mutant [14]. As previously reported [5], Vpu down-regulated endogenous BST-2 from the surface of HeLa cells as measured by flow cytometry (Figure 1A, left panel, in which transfection using a Vpu-expression plasmid reduced the mean fluorescence intensity (MFI) of the cells by 69%). Cells transfected to over-express wild-type β-TrCP also supported the efficient down-regulation of BST-2 by Vpu (a reduction of 77% in MFI; Figure 1A, middle panel). In contrast, ΔF-box β-TrCP inhibited the down-regulation of BST-2 by Vpu (a reduction of only 25% in MFI; Figure 1A, right panel). Immunoblot data indicated that the exogenous β-TrCP and ΔF-box β-TrCP proteins were expressed appropriately (Figure 1B). In four independent experiments, the activity of Vpu when wild-type β-TrCP was over-expressed relative to the activity of Vpu alone was 1.10 (standard deviation = 0.22), whereas the activity of Vpu when ΔF-box β-TrCP was expressed relative to the activity of Vpu alone was 0.40 (standard deviation = 0.20); p = 0.007 by Student's t test. The expression of Vpu was not differentially affected in cells expressing ΔF-box β-TrCP relative to cells expressing wild-type β-TrCP, weighing against an indirect mechanism for these effects (data not shown). The inhibition of Vpu-activity by ΔF-box β-TrCP supported key roles for β-TrCP and the linkage of Vpu to the β-TrCP/SCF E3 ubiquitin ligase complex during the down-regulation of BST-2. [Figure: β-TrCP is required for the optimal down-regulation of cell-surface BST-2: inhibition of Vpu activity by ΔF-box β-TrCP and shRNA targeting β-TrCP-1 and -2.(A) ΔF-box β-TrCP inhibits Vpu-mediated down-regulation of cell-surface BST-2. Cells (HeLa) were transfected with either an empty plasmid or a plasmid expressing Vpu, along with a plasmid expressing GFP as a transfection marker. The cells were also transfected with either an empty plasmid (“mock”), a plasmid expressing β-TrCP, or a plasmid expressing a β-TrCP